Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing safety and efficacy of VS-505(AP301) for treating hyperphosphatemia in hemodialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphosphatemia

Drugs mentioned

• VS-505(AP301)

Snippet

Sponsor: Shanghai Alebund Pharmaceuticals Limited | Conditions: Hyperphosphatemia | Phase 2 | Status: COMPLETED